Histone deacetylase (HDAC)-inhibitor drugs could be considered for treatment in the clinical scenario of upregulated MITF and SETD2 inhibitors are currently being investigated in the treatment of leukemia [25, 26]. The gene discussed is HDAC9; the disease is leukemia.